

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 2, line 20, before "November" insert --pages 947-953,--; and


Page 3, line 20, before "December" insert --pages 2503-2507,--; and

line 23, before "May" insert --pages 356-358--.


IN THE CLAIMS:

Please amend claims 1, 6, 9-11 and 15 as follows:

1. (Amended) A [selectively stable] compound [comprising the] of formula I:



wherein [one of] R₁ [or R₂ is independently an aliphatic hydrocarbon having] has the formula II:



[R₁ or] R₂[, which is other than formula II,] and R₃ are independently C₍₁₋₁₂₎ alkyl, optionally, one or more carbon atoms of the C₍₁₋₁₂₎ alkyl being replaced by an oxygen atom; and wherein:

C* is a chiral carbon atom;

n is [an integer from about] four [to about eight];

R_4 is [an] a naturally occurring amino acid or carbohydrate attached to the chiral carbon atom C^* by an ester linkage, or $-O-X-(R_5)_m$; m being two or three and X being selected from the group consisting of C, P or S; wherein:

R_5 is a member independently selected from the group consisting of:

hydrogen atom;

hydroxyl group;

$=O$;

substituted or unsubstituted $[C(1-10)]$, $C_{(3-10)}$ alkyl, $[C(1-10)] C_{(2-10)}$ alkenyl, $[C(1-10)] C_{(2-10)}$ alkynyl, $C_{(1-10)}$ alkoxy, $C_{(1-10)}$ oxoalkyl, or $C_{(1-10)}$ [acetoxyl] acetoxylalkyl, $C_{(1-10)}$ carboxyalkyl, [or] $C_{(1-10)}$ hydroxyalkyl, or substituted $C_{(1-2)}$ alkyl group;

$-OR_6$, R_6 being a substituted or unsubstituted $C_{(1-10)}$ alkyl, $[C(1-10)] C_{(2-10)}$ alkenyl, $[C(1-10)] C_{(2-10)}$ alkynyl, or $C_{(1-10)}$ oxoalkyl; and

substituted or unsubstituted [cyclic] carbocyclic or heterocyclic group having [from one- to three-] one or two rings, each ring containing from four to seven atoms.


6. (Amended) The compound of claim 1, wherein substituents for the substituted $C_{(1-10)}$ alkyl, $[C(1-10)] C_{(2-10)}$ alkenyl, $[C(1-10)] C_{(2-10)}$ alkynyl, $C_{(1-10)}$ alkoxy, $C_{(1-10)}$ oxoalkyl, or $C_{(1-10)}$ [acetoxyl] acetoxylalkyl, cyclic or heterocyclic groups are selected from the group consisting of [amido,] amino, $[C(1-6)] C_{(2-6)}$ alkenyl, $C_{(1-6)}$ alkyl, $C_{(1-6)}$ alkoxy, primary, secondary or tertiary $C_{(1-6)}$ hydroxyalkyl, $C_{(1-6)}$ oxoalkyl, azido, carbonyl, [carboxylic acid] carboxyalkyl, cyano, $C_{(1-6)}$ haloalkyl, isocyano, isothiocyanato, [phosphatyl, phosphonatyl, sulfonatyl] alkylphosphate, alkylphosphonate, alkylsulfonate, sulfonyl, sulfoxyl, imino, [thioamido,] thiocarbonyl, thioalkoxy[, thioloxoalkyl and thio groups] or a chlorine, bromine fluorine and oxygen [single] atom.

9. (Amended) The compound of claim 1, wherein one or two, nonadjacent carbon atoms of the R_1 or R_2 , other than formula II, [contains one or two, nonadjacent] are replaced with oxygen atoms[, each oxygen atom replacing a single carbon atom of the $C_{(1-12)}$ alkyl].


Claim 10, line 6, change "methylbenzoyleneureayl" to --methylbenzoyleneuryl--;
 line 7, change "octylcarboxamidobenzyl" to --octylcarboxamidophenyl--,
 "methylbenzamidyl" to --methylbenzamido--, and "methyldioxotetrahydropteridinyl" to
 --methyldioxotetrahydropteridyl--; and
 line 8, change "dimethoxybenzyl" to --dimethoxyphenyl--.

Claim 11, line 1, delete "n is 4".

15. (Amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound having the following formula I:



wherein one of R1 [or R2 is independently an aliphatic hydrocarbon having] has the formula II:



R1 or R2, which is other than formula II, and R3 are independently C₍₁₋₁₂₎ alkyl, optionally, one or more carbon atoms of the C₍₁₋₁₂₎ alkyl being replaced by an oxygen atom; and wherein:

C* is a chiral carbon atom;

n is an integer from [about] four to [about] eight];

R_4 is [an] naturally occurring amino acid or carbohydrate attached to the chiral carbon atom C^* by an ester linkage, or $-O-X-(R_5)_m$; m being two or three and X being selected from the group consisting of C, P or S; wherein:

R_5 is a member independently selected from the group consisting of:

hydrogen atom;

hydroxyl group;

$=O$;


substituted or unsubstituted $C_{(1-10)}$ alkyl, $[C_{(1-10)}] C_{(2-10)}$ alkenyl, $[C_{(1-10)}] C_{(2-10)}$ alkynyl, $C_{(1-10)}$ alkoxyl, $C_{(1-10)}$ oxoalkyl, or $C_{(1-10)}$ [acetoxy] acetoxyalkyl, $C_{(1-10)}$ carboxyalkyl or $C_{(1-10)}$ hydroxyalkyl group;

$-OR_6$, R_6 being a substituted or unsubstituted $C_{(1-10)}$ alkyl, $[C_{(1-10)}] C_{(2-10)}$ alkenyl, $[C_{(1-10)}] C_{(2-10)}$ alkynyl, or $C_{(1-10)}$ oxoalkyl; and


substituted or unsubstituted [cyclic] carbocyclic or heterocyclic group having [from one- to three-] one or two rings, each ring containing from four to seven atoms.

Please add new claim 20 as follows:

--20. A compound of formula I:



wherein one of R_1 or R_2 has the formula II:



R₁ or R₂, which is other than formula II, and R₃ are independently C₍₁₋₁₂₎ alkyl, optionally, one or more carbon atoms of the C₍₁₋₁₂₎ alkyl being replaced by an oxygen atom; and wherein:

C* is a chiral carbon atom;

n is an integer from five to eight;

R₄ is a naturally occurring amino acid or carbohydrate attached to the chiral carbon atom C* by an ester linkage, or -O-X-(R₅)_m; m being two or three and X being selected from the group consisting of C, P or S; wherein:

R₅ is a member independently selected from the group consisting of:

hydrogen atom;

hydroxyl group;

=O;

substituted or unsubstituted C₍₁₋₁₀₎ alkyl, C₍₂₋₁₀₎ alkenyl, C₍₂₋₁₀₎ alkynyl, C₍₁₋₁₀₎ alkoxyl, C₍₁₋₁₀₎ oxoalkyl, or C₍₁₋₁₀₎ acetoxyalkyl, C₍₁₋₁₀₎ carboxyalkyl or C₍₁₋₁₀₎ hydroxyalkyl group;

-OR₆, R₆ being a substituted or unsubstituted C₍₁₋₁₀₎ alkyl, C₍₂₋₁₀₎ alkenyl, C₍₂₋₁₀₎ alkynyl, or C₍₁₋₁₀₎ oxoalkyl; and

substituted or unsubstituted carbocyclic or heterocyclic group having one or two rings, each ring containing from four to seven atoms.--

Please cancel claim 8 without prejudice or disclaimer.

REMARKS

Claims 1, 6, and 9-11 and 15 are amended; claim 20 is new, claim 8 is canceled without prejudice or disclaimer of Applicants' right to file a continuation or divisional application